Post Top Ad


Wednesday, 29 July 2020

Hepatitis C drugs to treat Covid? PGIMS moots clinical trials

Sunit Dhawan

Tribune News Service

Rohtak, July 28

Medical experts engaged in the management and control of Covid believe that some drugs being used to treat Hepatitis C can be effective in the treatment of Covid patients as well.

They say Hepatitis C drugs Ledipasvir and Daclatasvir combined with Sofosbuvir can be more effective than Remdesivir and other drugs being used to treat Covid patients.

The Council for Scientific and Industrial Research National Chemical Laboratory (CSIR-NCL), Pune, in collaboration with INTOX Private Limited, Pune, and Post-graduate Institute of Medical Sciences (PGIMS), Rohtak, have sent a joint proposal to the Drug Controller General of India (DCGI) for permission to conduct trials of Hepatitis C drugs on Covid patients.

“The trials will begin once we receive the permission. Clinical trials are proposed to be conducted at the PGIMS, while other collaborators will take care of the in-vitro and in-silico aspects. We have also approached the Biotechnology Industry Research Assistance Council (BIRAC) for funding the project,” Dr Dhruva Chaudhry, head of the department of pulmonary and critical care medicine at the PGIMS, told The Tribune.

Prof Mahesh C Gupta, head of the department of pharmacology at the Pt BD Sharma University of Health Sciences, Rohtak, said the combination of Ledipasvir-Sofosbuvir and Daclatasvir-Sofosbuvir had been found to be effective against Covid in the studies conducted in Iran and other countries.

from The Tribune

No comments:

Post a comment